Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-β induced experimental model of Alzheimer's disease

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 46-57

  Prakash, Ajay ^a   Medhi, Bikash ^b   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Alzheimer's disease; GCSF; HSCs

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPLORATORY BEHAVIOR; HEMATOPOIETIC STEM CELL; LIPID PEROXIDATION; MALE; MEMORY; MOTOR COORDINATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; SHORT TERM MEMORY; TASK PERFORMANCE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

AD; ALZHEIMER'S DISEASE; AMYLOID-BETA (1-42); AΒ(1-42); BDNF; BRAIN-DERIVED NEUROTROPHIC FACTORS; CAT; CATALASE; DENTATE GYRUS; DG; EDTA; EPO; ERYTHROPOIETIN; ETHYLENEDIAMINE TETRACHLOROACETIC ACID; GCSF; GRANULOCYTE COLONY-STIMULATING FACTOR; GSH; HSCS; ICV; INTRACEREBROVENTRICULAR; MACHR; MUSCARINIC RECEPTOR; N-METHYL-D-ASPARTATE; NACHR; NBT; NICOTINIC RECEPTOR; NITRO BLUE TETRAZOLIUM; NMDA; REDUCED GLUTATHIONE; SOD; SUPEROXIDE DISMUTASE; TBA; THIOBARBITURIC ACID; TLT; TRANSFER LATENCY TIME;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BASE SEQUENCE; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION REGULATION; GRANULOCYTE COLONY-STIMULATING FACTOR; INDUCED PLURIPOTENT STEM CELLS; MALE; MEMORY; NITRITES; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR;

EID: 84879473776     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.05.015     Document Type: Article

References (61)

1. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, et al. Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 2010;7: 15-20.
2. Assaraf MI, Diaz Z, Liberman A, Miller Jr WH, Arvanitakis Z, Li Y, et al. Brain erythropoietin receptor expression in Alzheimer disease andmild cognitive impairment. JNeuropathol Exp Neurol 2007;66: 389-98. (Pubitemid 46701321)
3. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995;85: 1655-8.
4. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 2004;1000: 1-7. (Pubitemid 38446484)
5. Butterfield DA, Boyd-Kimball D.Amyloid beta-peptide (1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 2004;14: 426-32. (Pubitemid 39524972)
6. Butterfield DA, Boyd-Kimball D. The critical role ofmethionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 2005;1703: 149-56. (Pubitemid 40170438)
7. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002;32: 1050-60. (Pubitemid 34603342)
8. Carlsson G, Ahlin A, Dahllof G, Elinder G, Henter JI, Palmblad J. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol 2004;126: 127-32. (Pubitemid 38859493)
9. Cartimell SM, Grelgor L, Mitchell D. A revised Rotarod procedure for measuring the effect of antinociceptive drugs on motor function in the rat. J Pharmacol Methods 1991;26: 149-59.
10. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002;33: 562-71. (Pubitemid 34874977)
11. Claiborne A. Catalase activity. In: Greenwald RA, editor. Handbook of methods for oxygen radical research. Boca Raton: CRC; 1985. p. 283-4.
12. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 2005;8: 79-84. (Pubitemid 41236735)
13. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007;13(12):RA214-21. (Pubitemid 350272890)
14. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78: 2791-808.
15. Ding Q, Dimayuga E,Markesbery WR, Keller JN. Proteasome inhibition increases DNA and RNA oxidation in astrocyte and neuron cultures. J Neurochem 2004;91: 1211-8. (Pubitemid 39587459)
16. Ellman GL, Courtney DK, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7: 88-95.
17. Fernández-Verdecia CI, Díaz del Guante MA, Castillo-Díaz L, Alvarez-Blanco J. Neurogenesis as a therapeutic target for Alzheimer's disease. Rev Neurol 2009;9: 193-201.
18. Gibson CL, Bath PM, Murphy SP. G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005a;25: 431-9.
19. Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-CSF suppresses edema formation and reduces interleukin-1β expression after cerebral ischemia inmice. J Neuropathol Exp Neurol 2005b;64: 763-9. (Pubitemid 41285808)
20. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982;126: 131-8. (Pubitemid 13203451)
21. Guan ZZ. Cross-talk between oxidative stress and modifications of cholinergic and glutaminergic receptors in the pathogenesis of Alzheimer's disease. Acta Pharmacol Sin 2008;29: 773-80.
22. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65: 2146-56.
23. Hofer T, Marzetti E, Xu J, Seo AY, Gulec S, Knutson MD, et al. Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. Exp Gerontol 2008;43: 563-70.
24. Hou L, Hong T. Stem cells and neurodegenerative diseases. Sci China C Life Sci 2008;51: 287-94. (Pubitemid 351661099)
25. Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus maze for the evaluation of memory in mice. Effects of nootropic scopolamine and electroconvulsive shock. Psychopharmacology 1990;101: 27-32.
26. Jacobsen JS, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2005;2: 612-26. (Pubitemid 41393269)
27. Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide as the hepatotoxic intermediate. Pharmacology 1974;11: 151-69.
28. Kleinschnitz C, Schroeter M, Jander S, Stoll G. Induction of granulocyte colonystimulating factormRNA by focal cerebral ischemia and cortical spreading depression. Brain Res Mol Brain Res 2004;131: 73-8. (Pubitemid 39458279)
29. Kocherlakota P, La Gamma E. Human granulocyte colony-stimulating factormay improve outcome attributable to neonatal sepsis complicated by neutropenia. Pediatrics 1997;100:E6.
30. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 1978;186: 189-95. (Pubitemid 8290500)
31. Kulbatski I, Mothe AJ, Nomura H, Tator CH. Endogenous and exogenous CNS derived stem/progenitor cell approaches for neurotrauma. Curr Drug Targets 2005;6: 111-26. (Pubitemid 40403011)
32. Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001;97(10): 3075-85.
33. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998;19: 33-6. (Pubitemid 28167792)
34. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982;297: 681-3. (Pubitemid 12096189)
35. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006;50(5): 540-7.
36. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999;19: 1959-64. (Pubitemid 29133374)
37. ParkHK, ChuK, Lee ST, JungKH, KimEH, LeeKB, et al. Granulocyte colony-stimulating factor induces sensorimotor recovery in intracerebral hemorrhage. Brain Res 2005;1041: 125-31.
38. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362: 329-44.
39. Rowe A, Eberhard J, Sanchez-Ramos J. Hematopoietic growth factors: novel therapeutic strategy for Alzheimer's disease. Drugs Fut 2009;34: 977-89.
40. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 2008;4: 65-79.
41. Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience 2009;163: 55-72.
42. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 2000;31: 2212-7.
43. Seyfried D, Ding J, Han Y, Li Y, Chen J, Chopp M. Effects of intravenous administration of human bone marrow stromal cells after intracerebral hemorrhage in rats. J Neurosurg 2006;104: 313-8.
44. Seyfried DM, Han Y, Yang D, Ding J, Savant-Bhonsale S, Shukairy MS, et al. Mannitol enhances delivery of marrow stromal cells to the brain after experimental intracerebral hemorrhage. Brain Res 2008;1224: 12-9.
45. Shan X, Chang Y, Lin CL. Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J 2007;21: 2753-64. (Pubitemid 47372743)
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14: 837-42.
47. Sharma M, Gupta YK. Effect of chronic treatment of melatonin on learning, memory and oxidative deficiencies induced by intracerebroventricular streptozotocin in rats. Pharmacol Biochem Behav 2001a;70: 325-31. (Pubitemid 33051001)
48. Sharma M, Gupta YK. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 2001b;68: 1021-9. (Pubitemid 32168054)
49. Sharma M, Gupta YK. Chronic treatment with transresveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002;71: 2489-98. (Pubitemid 35251893)
50. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002;33: 1194-9. (Pubitemid 35246587)
51. Sobrino T, Arias S, Pérez-Mato M, Agulla J, Brea D, Rodríguez-Yáñez M, et al. CD34+ progenitor cells likely are involved in the good functional recovery after intracerebral hemorrhage in humans. J Neurosci Res 2011;89: 979-85.
52. Solaroglu I, Solaroglu A, Kaptanoglu E, Dede S, Haberal A, Beskonakli E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst 2003;19: 19-22. (Pubitemid 36798745)
53. Sprigg N, Bath PM, Zhao L, Willmot MR, Gray LJ, Walker MF, et al. Granulocyte-colonystimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery Enhancement after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke 2006;37: 2979-83. (Pubitemid 44913858)
54. Stephan A, Laroche S, Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci 2001;21: 5703-14. (Pubitemid 32692169)
55. Sultana R, Newman S, Mohmmad-Abdul H, Keller JN, Butterfield DA. Protective effect of the xanthate, D609, on Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress in primary neuronal cells. Free Radic Res 2004;38: 449-58. (Pubitemid 38618366)
56. Tuzcu M, Baydas G. Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur J Pharmacol 2006;537: 106-10.
57. Wills ED. Mechanism of lipid peroxide formation in animals. Biochem J 1965;99: 667-76.
58. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, et al. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001;133: 89-96.
59. Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 2010;22: 295-306.
60. Zhang H, Huang Z, Xu Y, Zhang S. Differentiation and neurological benefit of the mesenchymal stem cells transplanted into the rat brain following intracerebral hemorrhage. Neurol Res 2006;28: 104-12. (Pubitemid 43201837)
61. Zhao B, Zhong M, Jin K. Neurogenesis and neurodegenerative diseases in human. Panminerva Med 2008;50: 55-64.